MedTrace Logo

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone

NCT01552850 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-08-31

No results posted yet for this study

Summary

To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of four PF-00345439 formulations and oxycodone in solution

Conditions

Interventions

DRUG

Oxycodone

1X40 mg PF-00345439 formulation A capsule with water and under fed condition

DRUG

Oxycodone

1X40 mg PF-00345439 formulation B capsule with water and under fed condition

DRUG

Oxycodone

1X40 mg PF-00345439 formulation C capsule with water and under fed condition

DRUG

Oxycodone

1X40 mg PF-00345439 formulation D capsule with water and under fed condition

DRUG

Oxycodone

40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition

Sponsors & Collaborators

  • Pain Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01552850 on ClinicalTrials.gov